Opyl Ltd. (AU:PKY)
ASX:PKY
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$13.36M
Enterprise ValueAU$7.48M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI/ML Platform Focus For Life SciencesOpyl’s core focus on AI/ML for clinical trials and drug development aligns with a durable structural trend toward digitisation in life sciences. Platform-based analytics can scale across customers, improving stickiness and long-term revenue potential as pharma prioritises data-driven trial efficiency.
B2B Subscription And Services Revenue ModelA B2B subscription/licensing and services mix supports recurring and contract-based revenue streams if commercial traction is achieved. This model can deliver predictable cash inflows and higher lifetime customer value, enabling investment in product development and long-term customer relationships.
Very Lean Operating HeadcountAn extremely small employee base implies a lower fixed-cost structure, which can extend runway and reduce cash requirements while management pursues product-market fit. If scaled prudently, lean operations support efficient R&D allocation and slower cash burn during commercialization phases.
Bears Say
Sharp Revenue ContractionAn ~86% year-over-year revenue decline signals severe demand or execution issues that materially weaken the path to scale. Sustained top-line contraction impedes reinvestment in product, sales, and regulatory efforts, making it harder to achieve stable recurring revenue and market penetration.
Negative Shareholders' EquityNegative equity indicates cumulative losses have eroded the capital base, constraining the company’s ability to absorb shocks or secure favorable financing. This condition raises solvency concerns and increases dilution or refinancing risk, hampering long-term strategic options and partner confidence.
Persistent Cash Burn And Worsening FCFChronic negative operating and free cash flow, with material deterioration, means the business cannot self-fund growth and will rely on external capital. Ongoing cash burn elevates funding risk, may force dilutive financings, and limits sustained investment in sales and product needed to commercialise platforms.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$13.36M.
When is Opyl Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Opyl Ltd.’s earnings last quarter?
Currently, no data Available
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth AU$24.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---